Veeva Systems Inc Class ABrown Advisory exited Veeva due to competitive dynamics from Salesforce's life sciences push and AI landscape changes.
Brown Advisory's Large-Cap Growth Strategy exited its position in Veeva Systems during the first quarter of 2026, citing increasing uncertainty around competitive dynamics, particularly in CRM following Salesforce's push into the life sciences vertical, and the evolving role of vertical software in an AI landscape. The strategy noted these factors weighed on near-term visibility, and it reinvested the proceeds into Alnylam Pharmaceuticals. Veeva Systems closed at $192.74 per share on July 2, 2026, with a market capitalization of $31.31 billion, and its shares gained 32.20% over the past 52 weeks. The Brown Advisory Large-Cap Growth Strategy modestly trailed the Russell 1000 Growth Index in the first quarter, with Information Technology and Health Care as the largest detractors, while Industrials and Consumer Discretionary contributed positively.
Veeva Systems Inc Class ABrown Advisory exited Veeva due to competitive dynamics from Salesforce's life sciences push and AI landscape changes.
Salesforce.com IncSalesforce's push into life sciences CRM is cited as increasing competitive uncertainty for Veeva, implying a negative for Salesforce's competitive position.
Alnylam Pharmaceuticals IncBrown Advisory reinvested proceeds from Veeva into Alnylam, indicating a positive capital allocation view.
MicroStrategy Incorporated